You are here:

aprepitant (Emend)

Advice

following a full submission:

aprepitant (Emend®) is accepted  for use within NHS Scotland.

Indication under review: As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

A randomised, double-blind, placebo-controlled study demonstrated that the addition of aprepitant to a 5HT3 receptor antagonist (+/- steroid) in children and adolescents receiving chemotherapy with a moderate to very high emetogenic risk produced a significant anti-emetic benefit. 

Drug Details

Drug Name: aprepitant (Emend)
SMC Drug ID: 1241/17
Manufacturer: MSD
Indication: As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules). Aprepitant is given as part of combination therapy.
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 June 2017

Back